期刊文献+

肥厚型心肌病并发心房颤动的危险因素研究进展

Risk Factors of Hypertrophic Cardiomyopathy Complicated with Atrial Fibrillation
下载PDF
导出
摘要 肥厚型心肌病(HCM)是最常见的遗传性心肌病之一,人群患病率为1/200。HCM患者中并发心房颤动(房颤)者约占20%。心房颤动的发生使HCM患者心脏舒张功能进一步恶化,增加了缺血性卒中/体循环栓塞的发生率,在植入心脏复律除颤器的患者中诱发更多的不合理放电,导致HCM患者心血管死亡及全因死亡事件发生的概率升高,预后明显下降。HCM患者发生心房颤动与某些临床特征或遗传异质性相关,心电图、心脏超声和磁共振等影像学相关指标可以预测心房颤动发生的风险。通过HCM患者发生心房颤动的危险因素研究,有利于早期进行危险分层、心房颤动筛查和干预,从而改善其预后和生活质量。 Hypertrophic cardiomyopathy(HCM)is one of the most common genetic cardiac disorders and has a prevalence of 1/200.Atrial fibrillation(AF)occurs in approximately 20%of HCM patients.The occurrence of AF further deteriorates the impaired diastolic function,increases the risk of ischemic stroke/systemic embolism,and induces more unreasonable discharges in patients implanted with cardioverter defibrillator,which leads to an increased probability of cardiovascular death and all-cause death events in HCM patients.Some clinical features or genetic heterogeneity are susceptible to AF in HCM patients.Indicators from electrocardiogram,cardiac ultrasound and magnetic resonance imaging can predict the risk of AF occurrence.To summarize the risk factors of atrial fibrillation in patients with HCM can facilitate the risk stratification,screening and management of AF,thus improving the prognosis and quality of life in patients with HCM.
作者 马秀英 贾锋鹏 MA Xiuying;JIA Fengpeng(Chongqing Medical University Graduate School,Chongqing 400010,China;Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)
出处 《心血管病学进展》 CAS 2020年第12期1243-1246,共4页 Advances in Cardiovascular Diseases
关键词 肥厚型心肌病 心房颤动 危险因素 Hypertrophic cardiomyopathy Atrial fibrillation Risk factors
  • 相关文献

参考文献3

二级参考文献57

  • 1韦丙奇,翟玫,黄燕,叶蕴青,王运红,周琼,张宇辉,张健.肥厚型心肌病心力衰竭呈扩张型与限制型心肌病样改变患者临床特点分析[J].中华心力衰竭和心肌病杂志(中英文),2018,2(1):17-21. 被引量:3
  • 2Hogye M, Mandi Y, Csanady M, et al. Comparison of circulat- ing levels of interleukin6and tumor necrosis factor-alpha in hy pertrophic cardiomyopathy and in idiopathic dilated cardiomyop- athy[J]. Am J Cardiol,2004,94~249e51.
  • 3Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardio- myopathy: A report of the American college of cardiology foun- dation/American heart association task force on practice guide- lines [-J~. Circulation, 2011, 124 (24):e783.
  • 4Di Donna P, Olivotto I, Delcre SD, et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: Impact of age, atrial remodelling, and disease progression[J]. Europaee, 2010, 12 (3) :347.
  • 5Santangeli P, Di Biase L, Themistoclakis S, et al. Catheter ab- lation of atrial fibrillation in hypertrophic cardiomyopathy: Long-term outcomes and mechanisms of arrhythmia recurrence [J]. Circ Arrhythm Electrophysiol, 2013, 6 (6):1 089.
  • 6Mandyam MC, Soliman EZ, Alonso A, et al. The QT interval and risk of incident atrial fibrillation [J~. Heart Rhythm, 2013, 10 (10):1 562.
  • 7Nielsen JB, Graff C, Pietersen A, et al. J-shaped association between QTc interval duration and the risk of atrial fibrillation: Results from the copenhagen ECG study E J3. J Am Coll Cardi- ol, 2013, 61 (25):2 557.
  • 8Gray B, Ingles J, Medi C, et al. Prolongation of the QTc inter- val predicts appropriate implantable cardioverter-defibrillator therapies in hypertrophic cardiomyopathy I-J]. JACC.. Heart Failure, 2013, 1 (2):149.
  • 9Musat DL, Adhaduk M, Preminger MW, et al. Correlation of QT interval correction methods during atrial fibrillation and si- nus rhythm[J~. Am J Cardiol, 2013,112(9):1 379.
  • 10Jouven X, Hagege A, Charron P, et al. Relation between QT duration and maximal wall thickness in familial hypertrophic cardiomyopathy [J]. Heart, 2002, 88 (2):153.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部